NCT03837899 2024-10-29Durvalumab and Tremelimumab for Pediatric MalignanciesAstraZenecaPhase 1/2 Active not recruiting50 enrolled 59 charts
NCT03693612 2024-08-28GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid TumorsGlaxoSmithKlinePhase 1/2 Completed26 enrolled 47 charts
NCT03206073 2023-10-24A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal CancerNational Institutes of Health Clinical Center (CC)Phase 1/2 Completed34 enrolled 18 charts